These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35928456)

  • 1. Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.
    Li M; Mei S; Yang Y; Shen Y; Chen L
    Antib Ther; 2022 Jul; 5(3):164-176. PubMed ID: 35928456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant immunotoxins in targeted cancer cell therapy.
    Reiter Y
    Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
    Shan L; Liu Y; Wang P
    J Basic Clin Med; 2013; 2(2):1-6. PubMed ID: 25309827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells.
    Wang J; Han L; Chen J; Xie Y; Jiang H; Zhu J
    Int Immunopharmacol; 2019 Jan; 66():288-295. PubMed ID: 30502650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant immunotoxins for cancer therapy.
    Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P
    Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7.
    Cao L; Li Q; Tong Z; Xing Y; Xu K; Yijia Wang J; Li W; Zhao J; Zhao L; Hong Z
    Int J Pharm; 2020 Jan; 574():118939. PubMed ID: 31836485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxin-labeled monoclonal antibodies.
    Kreitman RJ
    Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer Immunotoxins, Challenges, and Approaches.
    Dashtiahangar M; Rahbarnia L; Farajnia S; Salmaninejad A; Shabgah AG; Ghasemali S
    Curr Pharm Des; 2021; 27(7):932-941. PubMed ID: 33023437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
    Dosio F; Brusa P; Cattel L
    Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
    Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
    Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.
    Niv R; Cohen CJ; Denkberg G; Segal D; Reiter Y
    Curr Pharm Biotechnol; 2001 Mar; 2(1):19-46. PubMed ID: 11482347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.
    Wu T; Zhu J
    Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
    MacDonald GC; Glover N
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
    Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
    Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
    Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
    BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.